Name: PROKIDNEY CORP (PROK) Stock
Brand: PROKIDNEY CORP
Rating: 6.5 (3 reviews)

PROK Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: ProKidney

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

5 days ago - By: ProKidney

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

14 days ago - By: ProKidney

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

14 days ago - By: ProKidney

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

3 months ago - By: The Motley Fool

Meet the Biotech Stock That Rocketed 775% Higher

4 months ago - By: Zacks Investment Research

ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?

a month ago - By: Benzinga - Mentions: OPEN MP SOFI SPCE ...

SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC

2 months ago - By: Benzinga - Mentions: GRI PACS XCUR REVB ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: ProKidney

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

2 months ago - By: ProKidney

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

2 months ago - By: The Motley Fool - Mentions: PLTR META MSFT AMZN ...

Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid

3 months ago - By: ProKidney

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

3 months ago - By: ProKidney

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

3 months ago - By: Yahoo Finance

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

4 months ago - By: Yahoo Finance - Mentions: JPM MS

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

4 months ago - By: Yahoo Finance

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

4 months ago - By: ProKidney

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

4 months ago - By: ProKidney

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

4 months ago - By: Yahoo Finance - Mentions: SHOP

PROKIDNEY CORP (PROK) Stock News

PROK Latest News, Press Relases and Analysis

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

Meet the Biotech Stock That Rocketed 775% Higher

ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?

SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC

12 Health Care Stocks Moving In Thursday's Intraday Session

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?